Eric Leip Selected Research

Tyrosine Kinase Inhibitors

1/2024	Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
12/2023	Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
1/2020	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
1/2018	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
12/2016	Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
9/2015	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
7/2014	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
4/2014	Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
2/2014	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
4/2012	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Leip Research Topics

Disease

15	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2024 - 10/2011
10	Philadelphia Chromosome 01/2024 - 10/2011
8	Leukemia 12/2023 - 04/2012
4	Blast Crisis (Blast Phase) 12/2021 - 09/2015
4	Diarrhea 01/2018 - 10/2011
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 09/2015
3	Disease Progression 01/2021 - 01/2018
2	Breast Neoplasms (Breast Cancer) 04/2014 - 04/2014
2	Exanthema (Rash) 04/2012 - 02/2012
1	Hypertension (High Blood Pressure) 06/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Cardiotoxicity 01/2016
1	Fever (Fevers) 09/2015
1	Pneumonia (Pneumonitis) 09/2015
1	Neoplasms (Cancer) 02/2012
1	Vomiting 02/2012
1	Fatigue 02/2012
1	Anorexia 02/2012
1	Nausea 02/2012
1	Coronary Disease (Coronary Heart Disease) 09/2003

Drug/Important Bio-Agent (IBA)

20	bosutinibIBA 01/2024 - 10/2011
14	Imatinib Mesylate (Gleevec)FDA Link 01/2024 - 10/2011
11	Tyrosine Kinase InhibitorsIBA 01/2024 - 02/2012
6	nilotinib FDA Link 01/2024 - 04/2012
6	Dasatinib (BMS 354825)FDA Link 01/2024 - 04/2012
3	Phosphotransferases (Kinase)IBA 01/2018 - 10/2011
2	Aromatase InhibitorsIBA 04/2014 - 04/2014
2	Hormones (Hormone)IBA 04/2014 - 04/2014
1	exemestane (Aromasin)FDA Link 04/2014
1	Letrozole (Femara)FDA LinkGeneric 04/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2014
1	Adenosine Triphosphate (ATP)IBA 02/2012
1	CholesterolIBA 09/2003

Therapy/Procedure

6	Therapeutics 12/2021 - 04/2012
3	Drug Tapering 12/2021 - 02/2014
1	Aftercare (After-Treatment) 06/2021